首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Development of chondroitin sulfate encapsulated PLGA microsphere delivery systems with controllable multiple burst releases for treating osteoarthritis.
【24h】

Development of chondroitin sulfate encapsulated PLGA microsphere delivery systems with controllable multiple burst releases for treating osteoarthritis.

机译:硫酸软骨素封装的PLGA微球递送系统的开发,该系统具有可控的多次爆发释放,可用于治疗骨关节炎。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of the study was to design and develop unique drug delivery systems with controllable multiple burst releases of drugs for treating osteoarthritis. Chondroitin sulfate (CS) was encapsulated into four types of PLGA materials, that is, PLGA 50:50, PLGA 65:35, PLGA 75:25, and PLGA 85:15. The effects of microsphere size and various combinations of blend PLGA microspheres on CS release were investigated. The cytotoxicity of the CS-encapsulated microspheres was investigated according to the ISO 10993 guideline. Our study showed that the encapsulation efficiency of CS into PLGA 50:50 microspheres varied with the size of microspheres; however, the encapsulation efficiencies of CS into PLGA microspheres were independent of the types of PLGA materials. The size of PLGA microspheres was shown to affect the rate of CS release. With the increase of microsphere size from 75-150 mum to 300-355 mum, the initial CS release decreased. Further increase in microsphere size led to an increase in the initial CS release. In addition, combination of different types of PLGA microspheres was shown to be capable of achieving multiple burst CS releases. Moreover, the CS encapsulated PLGA microspheres were shown to be non-cytotoxic. This study proved the concept of multiple burst drug releases that were achieved by encapsulating CS into different types of PLGA microspheres and delivering CS from systems consisting of mixed types of PLGA microspheres, which may be applied to treat osteoarthritis by mimicking multiple intra-joint injection of therapeutic agents.
机译:该研究的目的是设计和开发独特的药物输送系统,该系统具有可控制的多次突发性释放药物,用于治疗骨关节炎。将硫酸软骨素(CS)封装到四种PLGA材料中,即PLGA 50:50,PLGA 65:35,PLGA 75:25和PLGA 85:15。研究了微球尺寸和PLGA共混微球的各种组合对CS释放的影响。根据ISO 10993指南研究了CS包裹的微球的细胞毒性。我们的研究表明,CS到PLGA 50:50微球中的包封效率随微球的大小而变化。然而,CS到PLGA微球的包封效率与PLGA材料的类型无关。 PLGA微球的大小显示影响CS释放的速率。随着微球尺寸从75-150微米增加到300-355微米,初始CS释放减少。微球尺寸的进一步增加导致初始CS释放的增加。另外,显示出不同类型的PLGA微球的组合能够实现多次CS释放。此外,CS封装的PLGA微球被证明是无细胞毒性的。这项研究证明了通过将CS封装到不同类型的PLGA微球中并从混合类型的PLGA微球组成的系统中释放CS来实现多次突释药物的概念,可以通过模拟多次关节内注射来治疗骨关节炎。治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号